eli lilly glp 1 lawsuit Mounjaro - July 2026 Update Lilly asks to join lawsuit

PlexusDx explains how GLP-1 medications like tirzepatide can work alongside your thyroid treatment when properly monitored

At the same time, payer policies often require discontinuation of GLP-1 therapy when a patients BMI drops below a set threshold, inadvertently triggering a frustrating cycle of weight loss and regainthe so-called yo-yo effect. This not only impacts ongoing adherence and persistence but also undermines the long-term cost-effectiveness of these therapies for healthcare systems

Orforglipron, Lillys first small-molecule oral GLP-1 receptor agonist in Phase 3, showed meaningful weight loss and glycemic control in adults with type 2 diabetes and overweight or obesity

- Add flexibility without increasing overall cost

Is it worth it?